Summary & Overview
CPT 81536: Tumor Cell Culture, DAPI Staining, Predictive Drug Response Score
CPT code 81536 represents a specialized laboratory procedure that cultures live tumor cells from female reproductive organ or tissue specimens, assesses cell morphology and DAPI staining, and runs a predictive algorithm to produce a drug response score for a single drug or drug combination. This code is relevant nationally as precision oncology and ex vivo drug response testing expand clinical and research applications for individualized therapeutic decision support.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical service and typical laboratory setting, guidance on where the service fits in the diagnostic and therapeutic workflow, and discussion of reimbursement and coverage considerations as they relate to major national payers. The publication also outlines expected documentation elements, common billing modifiers, and interoperability implications for laboratory reporting and electronic health records.
The content provides a concise reference for clinicians, laboratory directors, coding professionals, and policy analysts seeking to understand CPT code 81536, including clinical context, claims processing touchpoints, and payer considerations that influence access and utilization at a national level.
Billing Code Overview
CPT code 81536 describes a laboratory service in which a lab analyst cultures live tumor cells from specimens obtained from female reproductive organs or tissues, examines cell morphology and performs DAPI (4’-6–diamidino–2–phenylindole) staining, and applies a predictive algorithm to generate a drug response score for a single drug or drug combination following an initial drug response score procedure.
-
Service type: Tumor cell culture, morphologic and DAPI staining analysis, and predictive algorithm drug response scoring
-
Typical site of service: Clinical laboratory or specialized pathology/molecular diagnostics laboratory receiving surgical or biopsy specimens from female reproductive organs
Clinical & Coding Specifications
Clinical Context
A 56-year-old woman with recurrent epithelial ovarian carcinoma undergoes tumor biopsy or surgical resection. Fresh tumor tissue or ascites-derived tumor cells are sent to a specialized laboratory for ex vivo culture and drug-response testing. The lab analyst receives the specimen, performs tissue disaggregation and culture to establish live tumor cell cultures derived from female reproductive organs, and stains cells with 4’,6-diamidino-2-phenylindole (DAPI) to evaluate nuclear morphology. A predictive algorithm is applied to imaging and staining data to derive an initial drug response score for a single chemotherapeutic agent or combination; a subsequent, separate procedure produces an additional drug response score for another agent or combination if ordered. Results are reported to the treating gynecologic oncologist, who integrates the predictive scores with clinical factors when considering systemic therapy options. Typical site of service is a certified clinical molecular or cellular diagnostics laboratory affiliated with an academic medical center or commercial reference lab; specimen collection occurs in an outpatient clinic, operating room, or interventional radiology suite and is shipped to the lab per chain-of-custody and viability protocols.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit for the evaluation and management of an established patient | Append when the lab procedure is billed on the same day as an E/M visit performed by the same provider and billing guidelines require modifier linkage |